10x Genomics (TXG) officer sells 7,826 shares to cover RSU tax

Rhea-AI Filing Summary

10x Genomics, Inc. director and officer Benjamin J. Hindson reported an open-market sale of 7,826 shares of Class A common stock at an average price of $18.5764 per share. According to the filing, the shares were sold to cover tax withholding obligations from vesting restricted stock units. After this transaction, Hindson directly owns 424,779 shares.

Insider Trade Summary

Net Seller: 7,826 shares ($145,379)

Net Sell 1 txn

Insider Hindson Benjamin J.

Role See Remarks

Sold 7,826 shs ($145K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	7,826	$18.5764	$145K

Holdings After Transaction: Class A Common Stock — 424,779 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hindson Benjamin J.

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CA 94588

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/23/2026		S(1)		7,826	D	$18.5764	424,779	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Remarks:

Title: President and Chief Scientific Officer; Exhibit 24.1 - Power of Attorney

	/s/ Randy Wu, as Attorney-in-Fact for Benjamin J. Hindson	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did 10x Genomics (TXG) report for Benjamin J. Hindson?

Benjamin J. Hindson reported selling 7,826 shares of 10x Genomics Class A common stock. The sale was an open-market transaction and was conducted to cover tax withholding obligations arising from the vesting of restricted stock units, according to the filing footnote.

At what price were Benjamin J. Hindson’s 10x Genomics (TXG) shares sold?

The 7,826 10x Genomics Class A shares were sold at an average price of $18.5764 per share. This price reflects the execution level for the tax-related sale connected to the vesting of restricted stock units noted in the footnote.

How many 10x Genomics (TXG) shares does Benjamin J. Hindson hold after the transaction?

After the reported transaction, Benjamin J. Hindson directly holds 424,779 shares of 10x Genomics Class A common stock. This post-transaction balance reflects his remaining direct ownership after the 7,826-share tax-related sale disclosed in the Form 4.

Why did Benjamin J. Hindson sell 10x Genomics (TXG) shares in this Form 4 filing?

The shares were sold to cover tax withholding obligations triggered by the vesting of restricted stock units. This indicates the transaction was related to equity compensation tax requirements rather than a discretionary portfolio reallocation, based on the footnote disclosure.

What type of transaction was reported for 10x Genomics (TXG) in this Form 4?

The Form 4 reports an open-market sale of non-derivative Class A common stock by Benjamin J. Hindson. The filing classifies it under transaction code “S” and specifies that the purpose was to satisfy tax withholding obligations from RSU vesting.